Advertisement

Intracavernosal Drug Therapy

  • A. Ledda

Abstract

Intracavernosal pharmacotherapy became popular between 1982 and 1983 when Virag [14] and Brindley [3] demonstrated that injection of papaverine, phentolamine, and phenoxybenzamine into the cavernosal body induces a penile erection. One year later Virag [15] proposed a therapeutic protocol based on “self-injection”. Patients suffering from penile erectile deficiency were examined, and those who showed a favorable response to intracavernous injections of papaverine were taught a technique that provides a “self-erection”. Zorgniotti and Lefleur [17] in 1985 proposed a combination of papaverine and phentolamine, and immediately thereafter the use of prostaglandin E1 (PGE1) became a common practice. This drug was preferred over the others because of its lower rate of side effects, prolonged erections, and priapism than that with papaverine or papaverine + phentolamine. Today the use of these drugs has become routine, and constitutes either singularly or in combination the first step of every therapeutic protocol that deals with erectile dysfunction.

Keywords

Erectile Dysfunction Corpus Cavernosum Penile Erection Intracavernous Injection Penile Tissue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abozeid M, Juenemann KP, Luo J, et al (1987) Chronic papaverine treatment: the effect of repeated injections on the simian erectile response and penile tissue. J Urol 138:1263–1266PubMedGoogle Scholar
  2. 2.
    Belcaro G, Fisher C, Veller M et al (1993) Screening asymptomatic subjects with subclinical arteriosclerotic lesions with arterial ultrasonic biopsy. The PAP study. VASA 22/23:232–240Google Scholar
  3. 3.
    Brindley GS (1983) Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence. Br J Psychiatry 143:332PubMedCrossRefGoogle Scholar
  4. 4.
    Conti G, Virag R (1989) Human penile erection and organic impotence. Normal hystology and hystopathology. In: Mayor G (ed) Urologia internationalis, vol 44. Karger, Basel, pp 303–308Google Scholar
  5. 5.
    Ledda A, Seccia M, Martegiani C, Tenaglia R (1988) 18 mesi di esperienze con le farmacoprotesi peniene. Presented at the 61st Congress of the SIU, Cagliari, 20–23 SeptemberGoogle Scholar
  6. 6.
    Levine S, Althof SE, Turner LA, Risen CB et al (1989) Side effects of self-administration of intracavernous papaverine and phentolamine fore the treatment of impotence. J Urol 141:54PubMedGoogle Scholar
  7. 7.
    Lue TF, Tanagho EA (1987) Physiology of erection and pharmacological management of impotence. J Urol 137:829PubMedGoogle Scholar
  8. 8.
    Michal V, Kramar R, Pospichal J, Hejhol L (1977) Arterial epigastricocavernous anastomosis for the treatment of sexual impotence. World J Surg 1:515PubMedCrossRefGoogle Scholar
  9. 9.
    Porst H (1994) Ten years of experience with various vasoactive drugs. Comparative studies in over 4000 patients. Int J Impotence Res 6[Suppl 1]:D149Google Scholar
  10. 10.
    Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ et al (1998) Impaired neur-ogenic and endothelium-mediated relaxation of arterial smooth muscle from diabetic men with impotence. N Engl J Med 320:1025Google Scholar
  11. 11.
    Sidi A, Cameron J, Duffy L, ND Lange P (1986) Intracavernous drug-induced erections in the management of male erectile dysfunction: experience with 100 patients. J Urol 135:704PubMedGoogle Scholar
  12. 12.
    Sidi A, Reddy P, Chen K (1988) Patient acceptance of and satisfaction with vasoactive intracavernous pharmacotherapy for impotence. J Urol 140:293PubMedGoogle Scholar
  13. 13.
    Stackl W, Hasun R, Merberger M (1988) Intracavernous injection of prostaglandin E1 in impotent men. J Urol 140:66–68PubMedGoogle Scholar
  14. 14.
    Virag (1982) Intracavernous injection of papaverine for erectile failure. Letter to the Editor. Lancet 2:938Google Scholar
  15. 15.
    Virag (1984) Intracavernous injection of papaverine as a diagnostic and therapeutic method in erectile failure. Angiology 35:79/87CrossRefGoogle Scholar
  16. 16.
    Virag R, Adaikan PG (1987) Effects of prostaglandin E1 on penile erection and erectile failure. J Urol 139:1010Google Scholar
  17. 17.
    Zorgniotti AW, Lefleur RS (1988) Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J Urol 133:39–41Google Scholar

Copyright information

© Springer -Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • A. Ledda

There are no affiliations available

Personalised recommendations